Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund

Marker Therapeutics agreed to a $25 million stock purchase deal with Chicago-based institutional investor Lincoln Park Capital Fund to help advance clinical trials for some of its immunotherapy products.

2023 UD Flyer Pitch winners bring home a combined $95,000

POWER 100 No. 1: Gene Woods at Atrium Health targets disparity in care, economic outcomes and more

The Weekly Rundown: Reimagining downtown, public bathrooms, unwelcome mask redux

State of downtown: A building-by-building look

CUPID research: Finding faster ways to pinpoint the deadliest strokes

Real Estate Roundup: Chicago firm buys apartments, Spec’s takes another spot

Report: Nashville has nation’s lowest industrial vacancy rate

Nando’s Peri-Peri rolling out online catering platform

Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund

Previous Local co-working venture secures space in Doral Center

Next Reboot of former Big Surf Wave Park as Tempe industrial park moves forward

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

QVC sells North Carolina warehouse damaged in fire for $21M

Women of Influence: Meet Karen Morrison, our Businesswoman of the Year

Harnett County fills in with more new homes, businesses with latest development

‘Healthy’ and affordable housing keys for sustainable downtown Winston-Salem growth, panelists say

Epic Brewing is closing, but new life is already in the works for its RiNo home

Sweetgreen expands menu offerings with dessert

MENU

FirstStar Group

More Stories

Shaun Hayes sentencing moved back